Glucagon Receptor Gene Mutation (Gly40Ser) in Human Essential Hypertension

The PEGASE Study

Eva Brand, Lise Bankir, Pierre-François Plouin, Florent Soubrier

Abstract—A missense mutation (Gly40Ser) in exon 2 of the glucagon receptor gene (GCG-R) was shown to reduce ligand affinity and impair cAMP response. We conducted a case-control study with a sample of 741 French hypertensive patients with moderate to severe hypertension and 412 normotensive control subjects, who were genotyped for this biallelic variant by use of hybridization with allele-specific oligonucleotides. The Gly40Ser polymorphism was not significantly associated with hypertension in the whole study population, although the frequency of 40Ser carriers in hypertensive subjects was double that in normotensive subjects (3.1% in hypertensives versus 1.5%; \( P = 0.087 \)). However, the separate analysis of both genders revealed that 40Ser allele carriers were significantly more frequent (\( P = 0.035 \)) among male patients (17/429; 4.0%) than among normotensive male controls (2/242; 0.8%), whereas no significant difference was observed in female subjects (6/312 in hypertensives and 4/170 in normotensives). Further studies are required to interpret the significance of this association. (Hypertension. 1999;34:15-17.)

Key Words: linkage, genetic ■ polymerase chain reaction ■ oligonucleotide ■ blood pressure ■ genotype

Several findings have offered significant support that the glucagon receptor gene (GCG-R) represents a putative candidate for predisposition to human essential hypertension. This hypothesis is drawn from the potential role of glucagon in the regulation of electrolyte and water homeostasis. Glucagon has long been known to be natriuretic, but this effect required high doses of the hormone and, intriguingly, was not reproduced when glucagon was infused into the renal artery. The mechanism of the natriuretic effect of glucagon has been recently elucidated. It involves a prior action of glucagon on the liver, stimulating cAMP formation and cAMP release into the circulation. Although cAMP is usually an intracellular messenger, it is now clear that it also behaves as an extracellular, interorgan mediator between liver and kidney. In the kidney, cAMP potently reduces solute and water reabsorption in the pars recta of the proximal tubule. This results in a significant increase in water, sodium, phosphate, and urea excretion. Accordingly, solute and water excretion by the kidney are permanently modulated by the intensity of cAMP release by the liver.

The effects of glucagon are mediated through its binding to a specific receptor (GCG-R), a 480–amino acid protein, which belongs to the superfamily of G protein–coupled transmembrane receptors. The recently described Gly40Ser missense mutation in exon 2 of this receptor results in a lower affinity of the receptor for glucagon and a reduced cAMP response in transfected cells. Carriers of the mutation have a significantly lower increase in plasma glucose concentration in response to glucagon infusion, suggesting that the mutation also results in a blunted cAMP response in humans. It is tempting to speculate that a decrease in receptor activity in vivo might contribute to common essential hypertension by reducing the renal natriuretic effect of glucagon. A case-control study showed that the Gly40Ser mutation of the GCG-R was 5-fold more common in essential hypertensives with 2 hypertensive parents (n = 130, 5%) than in normotensives (n = 90, 1%) in the white population of Australia. All hypertensive carriers of the mutation except 1 were women and had a later onset of hypertension (52±2 [SE] years; \( P < 0.0001 \)) than hypertensives not bearing this mutation. A case-control study was performed in a Sardinian group of non–insulin-dependent diabetic patients and nondiabetic subjects. Results are difficult to compare because the group of nondiabetic subjects is small, and some subjects are family related. This mutation was not found in a group of 188 Japanese.

To estimate the importance of the potentially functional Gly40Ser mutation of the GCG-R, we performed a large case-control study in the French population using this variant.

Methods

An association study was performed by comparing allele and genotype frequencies for the biallelic polymorphism of the GCG-R (Gly40Ser) in a group of hypertensive patients and in normotensive control subjects, as described below. Clinical characteristics of the 2 groups are listed in Table 1.
Study Population

Hypertensive Index Cases (PEGASE Study)
The Projet d’Etude des Gènes de l’Hypertension Artérielle Sèvère à modérée Essentielle (PEGASE) was designed to identify genes for susceptibility to moderate and severe hypertension. A total of 741 hypertensive cases were previously recruited in the PEGASE Study from 15 regions of France, according to the following criteria: white European origin with both parents born in France and 4 grandparents born in Europe, aged <60 years, diastolic blood pressure ≥145 mm Hg or systolic blood pressure ≥160 mm Hg with antihypertensive treatment or ≥100 mm Hg with treatment, creatinine level <1.5 mg/dL, and absence of proteinuria.

Normotensive Control Subjects
Normotensive unrelated control subjects (n=412), collected in preventive medicine centers in Paris and Nancy, had systolic blood pressure <145 mm Hg, diastolic blood pressure <90 mm Hg, and no history of antihypertensive treatment or of chronic disease. All individuals were of white European origin.

Genotyping Gly40Ser Polymorphism of the GCG-R Gene

One set of oligonucleotides was used to cover a part of exon 2 and to generate a polymerase chain reaction product of 196 bp in length (Table 2). The amplification was performed with 100 ng of DNA in a total volume of 50 μL containing 10 mmol/L Tris-HCl (pH 9), 50 mmol/L KCl, 15 mmol/L MgCl₂, 0.1% Triton X-100, 0.2 mg/mL BSA, 200 μmol/L dNTPs, 0.5 U Taq polymerase (Perkin Elmer). The samples were denatured at 94°C for 5 minutes, followed by 35 amplification cycles at 94°C for 45 seconds, 53°C for 1 minute, and 72°C for 1 minute and 1 cycle at 72°C for 10 minutes.

TABLE 1. Clinical Parameters of Hypertensive Subjects and Normotensive Controls

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n</th>
<th>Age, y</th>
<th>SBP, mm Hg</th>
<th>DBP, mm Hg</th>
<th>BMI, kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT (all)</td>
<td>741</td>
<td></td>
<td>175.0 (19.3)</td>
<td>109.8 (6.8)</td>
<td>28.0 (5.1)</td>
</tr>
<tr>
<td>HT men</td>
<td>429</td>
<td></td>
<td>173.2 (19.0)</td>
<td>110.1 (7.3)</td>
<td>28.3 (4.5)</td>
</tr>
<tr>
<td>HT women</td>
<td>312</td>
<td></td>
<td>177.3 (19.4)</td>
<td>109.4 (6.1)</td>
<td>27.6 (5.8)</td>
</tr>
<tr>
<td>NT (all)</td>
<td>412</td>
<td></td>
<td>123.3 (13.8)</td>
<td>76.3 (9.8)</td>
<td>24.3 (3.3)</td>
</tr>
<tr>
<td>NT men</td>
<td>242</td>
<td></td>
<td>127.0 (13.1)</td>
<td>78.5 (10.0)</td>
<td>25.0 (2.9)</td>
</tr>
<tr>
<td>NT women</td>
<td>170</td>
<td></td>
<td>117.8 (13.0)</td>
<td>72.9 (8.7)</td>
<td>23.3 (3.7)</td>
</tr>
</tbody>
</table>

Values are mean (SD). SBP and DBP indicate systolic and diastolic blood pressure; BMI, body mass index; HT, hypertensive subjects; and NT, normotensive subjects.

TABLE 2. Amplifiers and Allele-Specific Oligonucleotides Used to Detect the Variant Gly40Ser of the GCG-R Gene

<table>
<thead>
<tr>
<th>Oligonucleotide 5’-3’</th>
<th>Position</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>5’TGT CTG GTT GCT GTG GCA TGG 3’</td>
<td>Exon 2</td>
<td>Amplification of exon 2 (forward)</td>
</tr>
<tr>
<td>5’GAA GAG AAC TCA GGA AGT GC 3’</td>
<td>Exon 2</td>
<td>Amplification of exon 2 (backward)</td>
</tr>
<tr>
<td>5’AGC TCT ACG GTG ACC AG 3’</td>
<td>Exon 2</td>
<td>Genotyping G allele (Gly)</td>
</tr>
<tr>
<td>5’AGC TCT ACA GTG ACC AG 3’</td>
<td>Exon 2</td>
<td>Genotyping A allele (Ser)</td>
</tr>
</tbody>
</table>

Results

Table 3 displays the results of the association study. The frequency of the Gly40Ser mutation did not exhibit significant deviation from Hardy-Weinberg expectations in the case or control groups. In the whole population, the mutation was twice as frequent among hypertensives than among controls. However, this difference did not reach statistical significance (P=0.087). When genders were analyzed separately, a significant difference in genotype frequency was found between cases and controls in men (P=0.035) but not in women (Table 3).

Seventeen of 429 male hypertensives exhibited the mutation on at least 1 allele versus only 2 of 242 male normotensives (4.0% versus 0.8%).

Discussion

This is the largest case-control study ever performed with white hypertensives for the Gly40Ser mutation of the GCG-R. The Gly40Ser mutation is relatively rare (allele frequency <1% in normotensive controls of this study) and, as a consequence, the informational value of this marker is low for an association study. This low informational value is compensated by the large number of severe essential hypertensives who were included in this study and by the fact that the Gly40Ser mutation is a potentially functional variant. Although we did not find a significant difference in the whole group, the frequency of the 40Ser allele carriers was 2-fold higher in hypertensives than in normotensives. Further analysis of both genders separately revealed that the 40Ser allele was significantly more frequent in male hypertensives than in male controls. In contrast, Chambers and Morris found a difference for the Gly40Ser mutation frequency, which was restricted to women. In the absence of consistency between these results, either these associations are...
TABLE 3. Comparison of Genotype Distribution of the GCG-R Gly40Ser Polymorphism in Controls and Hypertensive Cases

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>All</th>
<th>Men</th>
<th>Women</th>
<th>All</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlyGly</td>
<td>718</td>
<td>96.9</td>
<td>412</td>
<td>306</td>
<td>98.1</td>
<td></td>
</tr>
<tr>
<td>GlySer</td>
<td>22</td>
<td>3.0</td>
<td>16</td>
<td>6</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>SerSer</td>
<td>1</td>
<td>0.1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>χ²</td>
<td>2.9</td>
<td>5.5</td>
<td>0.10</td>
<td>0.07</td>
<td>0.035</td>
<td>0.9</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

χ² comparisons are made between hypertensives and corresponding normotensive control groups for genotype frequencies.

References

Glucagon Receptor Gene Mutation (Gly40Ser) in Human Essential Hypertension: The PEGASE Study
Eva Brand, Lise Bankir, Pierre-François Plouin and Florent Soubrier

Hypertension. 1999;34:15-17
doi: 10.1161/01.HYP.34.1.15

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/34/1/15

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/